Interim recommendations for the use of the Janssen Ad26.COV2.S (‎COVID-19)‎ vaccine: interim guidance, first issued 17 March 2021, updated 15 June 2021

Download

English (PDF, 216.2 KB)

Pусский (PDF, 544.3 KB)

This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts (SAGE) on Immunization at its extraordinary meeting on 15 March 2021 and updated during its extraordinary meeting on 27 May 2021.

Declarations of interests were collected from all external contributors and assessed for any conflicts of interest.

The guidance is based on the evidence summarized in the background document on the Janssen Ad26.COV2.S (COVID-19) vaccine and the background paper on COVID-19 disease and vaccines.